A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib

• Published in: Clinical & translational oncology Vol. 10; no. 7; pp. 442 - 444
• Main Authors: Manzano, Ramón González, Navarro, Elena Martínez, Eugenieva, Elena, Morejón, Francisco José Fernández, Farré, José, Brugarolas, Antonio
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01-07-2008
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Base Sequence; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Case Reports; Codon, Nonsense; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Protein Kinase Inhibitors - therapeutic use; Quinazolines - therapeutic use; Receptor, Epidermal Growth Factor - genetics; Adenocarcinoma; Mutations; Nonsense; NSCLC; Lung cancer; EGFR
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-008-0229-2

Most of the somatic epidermal growth factor receptor (EGFR) mutations described to date in non-small-cell lung cancer (NSCLC) patients are located in the kinase domain and are considered activating mutations. Some of these mutations are associated with response to specific EGFR tyrosine kinase inhibitors (TKI) such as gefitinib and erlotinib. Here we report a case of a previously undescribed EGFR nonsense mutation in a lung adenocarcinoma patient who did not derive any clinical benefit with combination chemotherapy and erlotinib. To the best of our knowledge this is the second report in the literature describing an EGFR nonsense mutation in lung cancer patients.